Reduction in Serum Levels of Adhesion Molecules, Interleukin-6 and C-reactive Protein Following Short-term Low-dose Atorvastatin Treatment in Patients with Non-familial Hypercholesterolemia

Abstract

Hypercholesterolemia causes endothelial dysfunction, an early feature of atherosclerosis, leading to increased production of adhesion molecules and cytokines. The aim of this study was to investigate the effects of three months of treatment with low dose atorvastatin on serum levels of adhesion molecules, interleukin-6 (IL-6) and highly sensitive C-reactive protein (hs-CRP) in patients with non-familial hypercholesterolemia. Fifty-five patients with non-familial hypercholesterolemia were randomized to treatment with atorvastatin 10 mg/day or placebo for 3 months. Soluble intercellular adhesion molecules-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin, IL-6 and hs-CRP levels were measured to assess the inflammatory activity of the endothelium. There was a significant reduction in ICAM-1 at 2 weeks (p < 0.0001) with further reduction at 3 months (p < 0.0001). At 3 months, there were significant reductions in VCAM-1 (p < 0.02), IL-6 (p < 0.0001) and hs-CRP (p < 0.01), but an increase in E-selectin levels (p < 0.002). Treatment with statin was an independent determinant of change in ICAM-1 (p < 0.05) and IL-6 levels (p < 0.05) after correcting for anthropometric indices, blood pressure and lipid profile. Low-dose atorvastatin treatment leads to reduction in proinflammatory markers of endothelial function, suggesting an attenuation of endothelial activation and improvement in endothelial function, independent of lipid lowering. This may lead to a reduction in the progression of atherosclerosis.

Adhesion molecules - C-reactive protein - Interleukin-6 - Endothelial dysfunction - Hypercholesterolemia - Atorvastatin

References

• 1 The Scandinavian Simvastatin Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Survival study (4S).  Lancet. 1994;  344 1383-1389
• 2 Sacks F M, Pfeffer M A, Moye L A, Rouleau J L, Rutherford J D, Cole T G, Brown L, Warnica J W, Arnold J MA, Wun C C, Davis B R, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.  N Eng J Med. 1996;  335 1001-1009
• 3 The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.  N Engl J Med. 1998;  333 1349-1357
• 4 Downs Jr, Clearfield M, Weiss S, Whitney E, Shapiro D R, Beere P A, Langedorfer A, Stein E A, Kruyer W, Gotto A M Jr. for AFCAPS/TexCAPS Research group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS.  J Am Med Assoc. 1998;  279 1615-1622
• 5 Jukema J W, Bruschke A VG, van Boven A J, Reiber H C, Bal E T, Zwinderman A H, Jansen H, Boerma G JM, van Rappard F M, Lie K I; on behalf of the REGRESS Study group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin study (REGRESS).  Circulation. 1995;  91 2528-2540
• 6 Pitt B, Mancini G BJ, Ellis S G, Rosman H S, Park J-S, McGovern M E. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-1): reduction in atherosclerosis in progression and clinical events.  J Am Coll Cardiol. 1995;  26 1133-1139
• 7 Kjekhus J, Pedersen T R. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).  Lancet. 1994;  344 1383-1389
• 8 Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, Bernini F. HMG co-A reductase inhibitors reduce MMP-9 secretion by macrophages.  Arterioscler Throm Vasc Biol. 1998;  18 1671-1678
• 9 Rosenson R S, Tangney C C. Antiatherombotic properties of statins: implications for cardiovascular event reduction.  J Am Med Assoc. 1998;  279 1643-1650
• 10 Ridker P M, Rifai N, Pfeffer M A, Sacks S, Braunwald E. Long term effects of pravastatin on plasma concentration of C-reactive protein.  Circulation. 1999;  100 230-235
• 11 Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelial dependent coronary vasomotion in patients with hypercholesterolaemia.  Circulation. 1994;  89 2519-2524
• 12 Ross R. Atherosclerosis- an inflammatory disease.  N Engl J Med. 1999;  340 115-126
• 13 Cines D B, Pollak E S, Buck C A, Loscalzo J, Zimmerman G A, McEver R P, Pober J S, Wick T M, Konkle B A, Schwartz B S, Barnathan E S, McCrae K R, Hug B A, Schmidt A M, Stern D M. Endothelial cells in physiology and in the pathophysiology of vascular disorders.  Blood. 1998;  91 (10) 3527-3561
• 14 Vogel R A. Cholesterol lowering and endothelial function.  Am J Med. 1999;  107 (5) 479-487
• 15 Weber C, Erl W, Weber K SC, Weber P C. HMG co-A reductase inhibitors decrease CD 11b expression and CD 11b-dependent adhesion of monocytes to endothelium reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia.  J Am Coll Cardiol. 1997;  30 1212-1218
• 16 Kroon A A, Stalenhoef A F, Buikema H, Demacker P N, de Wilde P C, Leijten P A, van Gilst W H. The effect of cholesterol reduction on the endothelial function and progression of atherosclerosis in WHHL rabbits.  Atherosclerosis. 1993;  103 221-230
• 17 Treasure C B, Klein J L, Weintraub W S, Talley J D, Stillabower M E, Kosinski A S, Zhang J, Bocuzzi S J, Cedarholm J C, Alexander R W. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease.  N Engl J Med. 1995;  332 481-487
• 18 Scientific Steering Committee on behalf of the Simon Broome Register Group . Risk of fatal coronary heart disease in familial hypercholesterolaemia.  BMJ. 1991;  303(6807) 893-896
• 19 World Health Organisation .Physical Status. The use and interpretation of anthropometry. Geneva; WHO 1995
• 20 Friedwald W T, Levy R I, Fredrickson D S. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of preparative ultracentrifuge.  Clin Chem. 1972;  18 499-502
• 21 Kimura M, Kurose I, Russell J, Granger D N. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats.  Arterioscler Thromb Vasc Biol. 1997;  17 11 521-11 526
• 22 Simons L A, Sullivan D, Simons J, Celermajer D S. Effects of atorvastatin monotheraphy and Simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolemia.  Atherosclerosis. 1998;  137 197-203
• 23 O’Driscoll G, Green D, Taylor R R. Simvastatin, an HMG-Co enzyme A reductase inhibitor, improves endothelial function within 1 month.  Circulation. 1997;  95 1126-1131
• 24 Stroes E S, Koomans H A, de Bruin T W, Rabelink T J. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication.  Lancet. 1995;  346 467-471
• 25 Annuar R, Nawawi H, Azian M, Faridah I, Khalid B AK, Yusof K. Rapid improvement in endothelial function of patients with familial and non-familial hypercholesterolemia treated with atorvastatin and palmvitee.  Atherosclerosis. 2001;  2(2) 51
• 26 Annuar R, Nawawi H, Norafaedah Mohd  Nor, Muid S, Azian M, Khalid B AK, Yusoff K. Rapid improvement in endothelial function following atorvastatin treatment is progressive and sustained.  J Am Coll Cardiol. 2002;  39 (suppl 9) 22B
• 27 Collins T. Biology of disease; endothelial nuclear factor κB and the initiation of the atherosclerotic lesion.  Lab invest. 1993;  68 499-508
• 28 Barnes P J, Karin M. Nuclear κB - a pivotal transcription factor in chronic inflammatory disease.  N Engl J Med. 1997;  336 1066-1071
• 29 Ridker P M, Rifai N, Sacks F. Long term effects of Pravastatin on plasma concentration of C-reactive protein.  Circulation. 1999;  100 230-235
• 30 Strandberg T E, Vanhanen H, Tikkanen M J. Effects of statin on C-reactive protein in patients with coronary artery disease.  Lancet. 1999;  353 118-119
• 31 Ridker P M, Rifai N, Lowenthal S P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia.  Circulation. 2001;  103 1191-1193
• 32 Joukhadar C, Klein N, Prinz M. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolaemia.  Thromb Haemost. 2001;  85 47-51
• 33 de Maat M P, Kluft C, Hoogerbrugge N. No effects of pravastatin on C-reactive protein and fibrinogen level.  Fibrinolysis Proteolysis. 1999;  13 29
• 34 Riesen W F, Engler H, Risch M, Korte W, Noseda G. Short-term effects of atorvastatin on C-reactive protein.  European Heart Journal. 2002;  23 794-799
• 35 Van de Ree M A, Huisman M V, Princen H MG, Meinders A E, Kluft C. and The DALI-Study Group . Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus.  Atherosclerosis. 2003;  166 129-135
• 36 Arnalich F, Hernanz A, Maderuelo D L, Pena M, Camacho J, Macero R, Vazquez J J, Montiel C. Enhanced acute-phase response and oxidative stress in older adults with type II diabetes.  Horm Metab Res. 2000;  32 407-412
• 37 Gearing A J, Newman W. Circulating adhesion molecules in disease.  Immunol Today. 1993;  14 506-512
• 38 Carlos T M, Harlan J M. Leukocyte-endothelial adhesion molecules.  Blood. 1994;  84 2068-2101
• 39 Gearing A J, Hemingway I, Pigott R, Hughes J, Rees A J, Cashman S J. Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1 and VCAM-1: Pathological significance.  Ann NY Acad Sci. 1992;  667 324-331
• 40 Davignon J, Larksome R. Low density lipoprotein-independent effects of statins.  Cur Open Lip idol. 1999;  10 543-559
• 41 De Catering R, Libby P, Pang H B. et al . Nitric Oxide decreases cytokine-induced endothelial activation and selectively reduces endothelial expression of adhesion molecules and pro-inflammatory cytokines.  J Clint Invest. 1995;  96 60-68
• 42 Schmidt G W, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site.  Nature Medicine. 2001;  7 687-692
• 43 Youssef S, Stüve O, Patarroyo J C, Ruiz J P, Radosevich J L, Hur E M, Bravo M, Mitchell D J, Sobel R A, Steinman L, Zamviltž S S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.  Nature. 2002;  420 78-84
• 44 Hackman A, Abe Y, Insull W, Pownall H, Smith L, Dunn K, Gotto Jr A M, Ballyntyne C M. Levels of soluble cell adhesion molecules in patients with dyslipidaemia.  Circulation. 1996;  93 334-1338
• 45 Ridker P M, Hennekens C H, Roitman-Johnson B, Stampfer M J, Allen J. Plasma concentration of soluble intercellular adhesion molecule-1 and risks of future myocardial infarction in apparently healthy men.  Lancet. 1998;  351 88-92
• 46 Ridker P M, Hennekens C H, Buring J E, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.  N Engl J Med. 2000;  342 837-843
• 47 Athyros V G, Papageorgiou A A, Mercouris B R, Athyrou V V, Symeonidis A N, Basayannis E O, Demitriadis D S, Kontopoulos A G. Treatment with atorvastatin to the National Cholesterol Education Program versus ‘usual’ care in secondary coronary heart disease prevention.  Current Medical Research and Opinion. 2002;  18 220-228
• 48 Nadar S, Lim H S, Beevers D G, Lip G YH. Lipid lowering in hypertension and heart protection: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study.  Journal of Human Hypertension. 2002;  16 815-817